Gain Therapeutics (GANX) to Release Earnings on Tuesday

Gain Therapeutics (NASDAQ:GANX) is expected to announce its Q1 2025 earnings results before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter.

Gain Therapeutics (NASDAQ:GANX) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.07. On average, analysts expect Gain Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Gain Therapeutics Stock Down 1.7 %

NASDAQ:GANX traded down $0.04 on Tuesday, reaching $2.00. The stock had a trading volume of 62,473 shares, compared to its average volume of 303,516. The stock has a market cap of $58.71 million, a P/E ratio of -1.80 and a beta of 0.17. The company has a current ratio of 2.99, a quick ratio of 2.99 and a debt-to-equity ratio of 0.04. Gain Therapeutics has a 12-month low of $0.89 and a 12-month high of $3.19. The company has a 50-day moving average of $1.94 and a 200 day moving average of $2.05.

Analyst Ratings Changes

Several research firms have recently issued reports on GANX. HC Wainwright reiterated a “buy” rating and set a $8.00 price target on shares of Gain Therapeutics in a research note on Monday, March 17th. Chardan Capital reiterated a “buy” rating and set a $6.00 price target on shares of Gain Therapeutics in a research report on Friday, March 28th. Finally, Scotiabank began coverage on shares of Gain Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $12.00 target price on the stock. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Gain Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $8.20.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.